Skp, the expert oral and inhalation drug development company, announces that its oral business has signed an exclusive feasibility, development and licence agreement with lucideon limited, part of lucideon group ltd lucideon, the international materials development and commercialisation. The company operates as an independent developer of complex pharmaceutical products for global markets. On 10 june 2016 vectura completed a merger with skyepharma. Skyepharma controlled release expertise is the result of years as a leader in drug development and oral drug delivery technologies serving the global pharmaceutical industry. At december 31, 2005, the net book value of the tangible assets pledged as.
Ken cunningham chief executive officer skyepharma plc. You have to know whats happening with clients, competitors, practice areas, and industries. Food and drug administration fda in 2004 for use as a postsurgical pain reliever. The transition date to ifrs for skyepharma plc is january 1, 2004. Depodur cii, previously known as depomorphine, is a morphine sulfate extendedrelease liposome injection see depot injection, product of pacira pharmaceuticals formerly skyepharma plc. Skyepharma fully integrated cdmo pharmaceutical oral solid. Skyepharma ltd, formerly skyepharma plc, is a drug delivery company engaged in the development of oral and inhalation products. With breakeven in sight, the company yesterday surprised the. In 1999 it acquired coordinated drug development and the centre for drug formulation studies.
Sph stock quote sinclair pharma plc bloomberg markets. Since it was founded, skyepharma has had a strong focus on oral drug delivery, solving the many challenges of delivering the right dose of a drug to the right part of the gastrointestinal system for absorption at the right time and at the appropriate rate to achieve the desired therapeutic effect. Technologies and global markets, provides a detailed overview and detailed analysis of. The share data supplied on this page is provided by aj bell media and incorporates share prices, market news, indices, charts, fundamentals, heatmaps, stock screeners and investor research tools. Skyepharma plc does not currently have any hardcopy reports on. Skyepharma plc 4648 grosvenor gardens london, greater london sw1 w0eb phone. Skyepharma is teetering on the brink of joining one of the most exclusive clubs in town drugs research companies which make profits. Prnewswire announces that a new market research report is available in its catalogue. This bcc research market research report, pulmonary drug delivery systems. The shares were originally acquired consequent upon the acquisition of the assets of hyal pharmaceutical corp. Skyepharma strives to deliver clinical benefits for patients by using its multiple delivery technologies to create enhanced versions of existing pharmaceutical.
This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in skyepharma plc the company nor shall it form the basis of or be relied on in. Vectura presents latest science at digital rdd 2020. Skyepharma plc clarification of financial position biospace. Skyepharma signs exclusive licensing agreement to access lucideons abuse deterrent drug delivery technology. Skyepharma has not attributed a value to these shares and they have been recorded at zero cost. View ken cunninghams profile on linkedin, the worlds largest professional community. Pharma job opportunities at skyepharma discover our cdmo. The name change reflects paciras transformation from a former business unit of skyepharma plc to an independent, private company with existing commercial products, a strong product in clinical development, and novel drug delivery. Skyepharma plc has announced its plans to acquire depotech corp. The share data supplied on this page is provided by aj bell media and incorporates share prices, market news, indices, charts, fundamentals, heatmaps, stock. Working at skyepharma means being part of a team that is united, aligned and committed to the development of our facility. The company was formed in 1997 as a startup pharmaceuticals business. Skyepharma is part of the vectura group of companies lse. Shares provides unbiased commentary, ideas, views and news on stocks, funds, pensions and savings.
Skyepharma is a speciality drug delivery company with a proven range of oral and inhalation technologies. Vectura will present some of its most recent science in five poster presentations at the virtual respiratory drug delivery rdd. Free forex prices, toplists, indices and lots more. Make sure your doctor knows if you are pregnant or breastfeeding, or if you have a history of asthma, stomach ulcers or bleeding, liver disease, kidney disease, or if you have ever had breathing problems after taking aspirin or another type of nsaid. We provide tailormade solutions to our customers by positioning ourselves as an integrated partner offering a wide range of premium services. Skyepharma plc clarification of financial position read this article along with other careers information, tips and advice on biospace. Skyepharma said its overall trading performance to endapril has been good and that directors continue to expect strong growth in revenues for fy 2016 compared with fy 2015. Skyepharma plc annual and transition report foreign private issuer 20f. Director deals skyepharma plc skp peter grant, chief executive officer, bought 32 shares in the company on the 29th april 2016 at a price of 473. Stock analysis for sinclair pharma plc sph including stock price, stock chart, company news, key statistics, fundamentals and company profile.
Ian gowriesmith, founder of medeva, creates skyepharma plc as a virtual entity. Click the button below to request a report when hardcopies become available. Uk key executives, insider trading, ownership, revenue and average growth rates. Skp skyepharma is a drug research and development company with a leading drug deliveries technology business, specialising in. Skyepharmas audit committee has invited tenders from certain qualified auditing firms and the company will make a further announcement in due course when a new auditor has been. In 2004 it was listed on the alternative investment market. Skyepharma then acquires jago ag, operating under that. In 2007 it acquired innovata plc, another developer of pulmonary products, and then moved on the full list of the london stock exchange.
Skyepharma share price history historical data for skp. Latest company news for skyepharma stock market wire. Whatever their position, each employee contributes to the development of the site. Skp dividends per share explanation, calculation, historical data and more.
Helping you bring inhaled medicines to market vectura. Both companies make treatments for asthma and other. Summary live market news shares comment trades director deals broker forecasts fundamentals historic prices. Vec, an industryleading device and formulation company specialized in airways disease.
Skyepharma is a cdmo with expertise in classic and complex oral solid dosage forms. Our value proposal includes tailored services to clients requirements supporting them up to market introduction. Founded in 1993 by brothers tom and david gardner, the motley fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and. Through many years of involvement and achievements in the pharmaceutical industry, skyepharma s development and manufacturing facility is a leader in the field of classic and complex oral solid dosage forms. Skyepharma strives to deliver a clinical benefit for patients by using its multiple delivery technologies to create enhanced versions of existing pharmaceutical products as well as products incorporating new chemical entities. In the legal profession, information is the key to success. The motley fool uk has recommended hikma pharmaceuticals. Is skyepharma plc a better buy than shire plc or hikma pharmaceuticals plc. Vectura group services limited free company information from companies house including registered office address, filing history, accounts, annual return, officers, charges, business activity. Investing in biotechnology stocks by leo gough, hardcover. Skyepharma plc annual and transition report foreign. View profile view profile badges view similar profiles. Skyepharma plc skyepharma or the company and vectura group plc vectura publication of scheme document on 16 march 2016, the boards of skyepharma and vectura announced that they had reached agreement regarding the terms of a recommended merger the merger.
995 193 250 967 1368 1448 294 775 1091 120 1032 214 1170 1084 1178 1431 731 419 83 134 127 515 238 1320 188 1097 369 479 1004